ClinicalTrials.gg
CompletedNCT03820986Updated Feb 9, 2026Results posted

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

A Phase 3 interventional study of Pembrolizumab and Lenvatinib in Malignant Melanoma, sponsored by Merck Sharp & Dohme LLC. Completed at 119 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
674
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing lenvatinib in Melanoma — 3 open to participants now, 5 under way, none of them phase 3. lenvatinib · Melanoma.

Enrollment
Largest of 18
674 · median 41
Started
2019
the only one that year
Phase 3
2 of 18
none open now
Registered
5th of 18
by date
Lead sponsor
4 of 18
Merck Sharp & Dohme LLC

Among the 18 studies testing lenvatinib in Melanoma, this one has the largest enrollment, is the only one that started in 2019, is one of 2 in phase 3, and was the 5th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 18 studies testing lenvatinib in Melanoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing lenvatinib in Melanoma, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in adults with no prior systemic therapy for their advanced melanoma.

The primary study hypotheses are that: 1) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab and placebo as assessed by Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), and 2) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab and placebo as assessed by Overall Survival (OS). For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

Read the detailed description

As of 03-April-2023 active participants, investigator, and sponsor personnel or delegate(s) involved in the treatment administration or clinical evaluation of the participants will be unblinded.

03

Conditions studied

  • Malignant Melanoma

Browse trials for

Keywords

  • programmed cell death 1 (PD-1, PD1)
  • programmed cell death-ligand 1 (PD-L1, PDL1)
  • programmed cell death-ligand 2 (PD-L2, PDL2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has or cytologically confirmed melanoma.
  • Has unresectable Stage III or Stage IV melanoma, as per American Joint Committee on Cancer guidelines, not amenable to local therapy.
  • Has been untreated for advanced or disease except as follows:

    1. Proto-oncogene B-Raf (BRAF) V600 mutation-positive melanoma may have received standard of care targeted therapy as therapy for advanced or metastatic disease. Participants that do not have a BRAF V600 mutation but did receive BRAF or BRAF/mitogen-activated extracellular signal-regulated kinase 1/2 Inhibitor (MEKi) therapy are eligible to participate in this study after discussion with the medical monitor.
    2. Prior or neoadjuvant therapy, with targeted therapy or immunotherapy (such as anti-cytotoxic T-lymphocyte-associated protein 4 [], anti-programmed cell death 1 [anti-PD-1] therapy or interferon) will only be permitted if relapse did not occur during active treatment or within 6 months of treatment discontinuation.
  • Have documentation of BRAF V600-activating mutation status or consent to BRAF V600 mutation testing during the Screening period (participants with BRAF mutation-positive melanoma as well as BRAF wild-type or unknown are eligible).
  • Has an (ECOG) performance status 0 to 1.
  • Has the presence of ≥1 by computed tomography (CT) or magnetic resonance imaging (MRI) per 1.1.
  • Provides a tumor . Participants must submit tumor sample during Screening for confirmation of adequacy of tumor tissue at a central pathology laboratory. Participants who do not submit a tumor tissue sample will not be randomized. The tumor biopsy may not be obtained from a lone target lesion. Confirmation of presence of tumor tissue is not required prior to randomization.
  • Has resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia). If participant received major surgery or radiation therapy of >30 Gray (Gy), they must have recovered from the toxicity and/or complications from the intervention.
  • Male participants must agree to use during the treatment period and for at least 7 days after the last dose of study treatment and refrain from donating sperm during this period. Please note that 7 days after lenvatinib/placebo is stopped, if the participant is on pembrolizumab only, no male contraception measures are needed. Contraception use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions is more stringent than the requirements above, the local label requirements are to be followed.
  • Female participants must not be pregnant, not breastfeeding, and ≥1 of the following conditions applies:

    1. Not a woman of (WOCBP). OR
    2. A WOCBP who agrees to use study-approved contraception during the treatment period and for at least 120 days after the last dose of study treatment.
  • The participant (or legally acceptable representative) has provided documented for the study.
  • Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mmHg at screening and no change in antihypertensive medications within 1 week before Cycle 1 Day 1.
  • Has adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days before the first dose of study treatment.
  • Has a known additional that is progressing or requires active treatment. Exceptions include early stage cancers (carcinoma in situ or Stage 1, non-ulcerated primary melanoma \<1 mm in depth with no nodal involvement) treated with curative intent, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast cancer that has undergone potentially curative therapy.
  • Has known active central nervous system and/or carcinomatous meningitis.
  • Has ocular melanoma.
  • Has known to active substances or any of their including previous hypersensitivity reaction to treatment with another monoclonal antibody.
  • Has an active disease that has required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • Has an active infection requiring systemic therapy.
  • Has known history of (HIV) infection
  • Has known history of or is positive for virus or virus infection.
  • Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  • Has a history of active tuberculosis (Bacillus tuberculosis).
  • Gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib.
  • Has had a major surgery within 3 weeks prior to first dose of study intervention. Note: Adequate wound healing after major surgery must be assessed clinically independent of time elapsed for eligibility.
  • Has a preexisting Grade ≥3 gastrointestinal or non-gastrointestinal fistula.
  • Has radiographic evidence of encasement or invasion of major blood vessel, or of intratumoral cavitation.
  • Has active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study treatment.
  • Has clinically significant cardiovascular disease from 12 months of the first dose of study treatment including Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability.
  • Has urine protein ≥1 g/24-hour. Note: Participants with ≥2+ (≥100 mg/dL) proteinuria on urine dipstick testing (or urinalysis) will undergo 24-hour urine collection for quantitative assessment of proteinuria.
  • Prolongation of interval to >480 ms. Note: If the QTcF is prolonged to >480 ms in the presence of a pacemaker, contact the Sponsor to determine eligibility.
  • Has (LVEF) below the institutional (or local laboratory) normal range, as determined by multigated acquisition scan (MUGA) or echocardiogram.
  • Has received prior therapy in the setting. Note: Targeted therapy, , or anti-PD-1 may be allowed.
  • Has received prior systemic treatment for unresectable or metastatic melanoma other than targeted therapy as noted in Inclusion Criteria above
  • Has received prior therapy with a monoclonal antibody, chemotherapy, or an agent or device within 4 weeks or 5 half-lives (whichever is longer) before administration of study treatment or not recovered (≤Grade 1 or at Baseline) from adverse events due to previously administered agents.

Exception to this rule would be use of denosumab, which is not excluded. Note: Participants with alopecia and ≤Grade 2 neuropathy are an exception and may enroll.

  • Has received prior radiotherapy within 2 weeks of first dose of study treatment (Cycle 1 Day 1). Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.
  • Has received within 30 days before the first dose of study treatment.
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
  • Has had an allogeneic tissue/solid organ transplant.
  • Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
674 participants (actual)

Study arms

  • Experimental
    Pembrolizumab+Lenvatinib

    Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule daily for up to at least 2 years.

    Biological: Pembrolizumab · Drug: Lenvatinib

  • Active comparator
    Pembrolizumab+Placebo

    Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule daily for up to at least 2 years.

    Biological: Pembrolizumab · Drug: Placebo for lenvatinib

Interventions

  • BiologicalPembrolizumab

    IV infusion

    Also known as: MK-3475, KEYTRUDA®

  • Oral capsule

    Also known as: MK-7902, E7080, LENVIMA®

  • DrugPlacebo for lenvatinib

    Oral capsule

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    PFS is defined as the time from date of randomization to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The final analysis for this outcome is presented here.

    Time frame: Up to approximately 34 months

  2. Overall Survival (OS)

    OS is defined as the time from date of randomization to date of death from any cause. The final analysis for this outcome is presented here.

    Time frame: Up to approximately 46 months

Secondary outcomes

  1. Objective Response Rate (ORR) as Assessed by BICR Per RECIST 1.1

    ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The final analysis for this outcome is presented here.

    Time frame: Up to approximately 46 months

  2. Duration of Response (DOR) as Assessed by BICR Per RECIST 1.1

    For participants who demonstrated CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), DOR is defined as the date of the first documented evidence of CR or PR until disease progression or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The final analysis for this outcome is presented here.

    Time frame: Up to approximately 46 months

  3. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The final analysis for this outcome is presented here.

    Time frame: Up to approximately 67 months

  4. Number of Participants Who Discontinue Study Treatment Due to Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued any study treatment due to an AE is presented. The final analysis for this outcome is presented here.

    Time frame: Up to approximately 63 months

  5. Change From Baseline in European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire-Core 30 [QLQ-C30] Global Health Status (GHS)/Quality of Life (QoL) Score

    The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The GHS/QoL combined score consists of participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" GHS/QoL responses range in score from 0 to 100, with a higher score indicating a better outcome. The final analysis for this outcome is presented here.

    Time frame: Baseline and Week 21

  6. Change From Baseline in European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire-Core 30 [QLQ-C30] Physical Function (PF) Score

    The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The PF Score consists of participant responses to questions regarding PF (5 questions about daily activities \[strenuous activities, long walks, short walks, bed/chair rest and needing help with eating, dressing, washing themselves or using the toilet\]). For PF, responses range in score from 0 to 100, with a higher score indicating a better outcome. The final analysis for this outcome is presented here.

    Time frame: Baseline and Week 21

  7. Time to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 GHS/QoL Score

    TTD is defined as the time from Baseline to 1st onset of a ≥10-point negative change (decrease) in EORTC-QLQ-C30 GHS Score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The GHS/QoL Score consists of participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" GHS/QoL responses range in score from 0 to 100, with a higher score indicating a better outcome. A longer TTD indicates a better outcome. The final analysis for this outcome is presented here.

    Time frame: Up to approximately 30 months

  8. Time to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 in Physical Function (PF) Score

    TTD is defined as the time from Baseline to 1st onset of a ≥10-point negative change (decrease) in EORTC-QLQ-C30 PF Score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The PF Score consists of participant responses to questions regarding PF (5 questions about daily activities \[strenuous activities, long walks, short walks, bed/chair rest \& needing help with eating, dressing, washing themselves or using the toilet\]. For PF, responses range in score from 0 to 100, with a higher score indicating a better outcome. The final analysis for this outcome is presented here.

    Time frame: Up to approximately 30 months

07

Results

Posted Jan 17, 2024

Participant flow

Participant flow — Overall Study
MilestonePembrolizumab+LenvatinibPembrolizumab+Placebo
Started334340
Treated332338
Completed00
Not completed334340
Withdrew: Death201175
Withdrew: Lost to follow-up11
Withdrew: Physician decision10
Withdrew: Sponsor decision122160
Withdrew: Withdrawal by subject94

Outcome measures

PrimaryProgression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

PFS is defined as the time from date of randomization to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The final analysis for this outcome is presented here.

Time frame:
Up to approximately 34 months
Reported as:
Median · Months
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
MonthsPembrolizumab+LenvatinibPembrolizumab+Placebo
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)9.1 (6.4 to 11.8)4.2 (3.1 to 6.3)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Pembrolizumab+Placebo · Log Rank · p = 0.0176 · Hazard ratio (hr): 0.81 · 95% CI 0.67 to 0.98HR=Pembrolizumab + Lenvatinib vs. Pembrolizumab + Placebo
PrimaryOverall Survival (OS)

OS is defined as the time from date of randomization to date of death from any cause. The final analysis for this outcome is presented here.

Time frame:
Up to approximately 46 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumab+LenvatinibPembrolizumab+Placebo
Overall Survival (OS)25.8 (23.0 to 33.9)39.5 (26.6 to NA)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Pembrolizumab+Placebo · Log Rank · p = 0.9521 · Hazard ratio (hr): 1.20 · 95% CI 0.97 to 1.48HR=Pembrolizumab + Lenvatinib vs. Pembrolizumab + Placebo
SecondaryObjective Response Rate (ORR) as Assessed by BICR Per RECIST 1.1

ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The final analysis for this outcome is presented here.

Time frame:
Up to approximately 46 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) as Assessed by BICR Per RECIST 1.1
Percentage of participantsPembrolizumab+LenvatinibPembrolizumab+Placebo
Objective Response Rate (ORR) as Assessed by BICR Per RECIST 1.143.4 (38.0 to 48.9)35.6 (30.5 to 40.9)
SecondaryDuration of Response (DOR) as Assessed by BICR Per RECIST 1.1

For participants who demonstrated CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), DOR is defined as the date of the first documented evidence of CR or PR until disease progression or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. The final analysis for this outcome is presented here.

Time frame:
Up to approximately 46 months
Reported as:
Median · Months
Duration of Response (DOR) as Assessed by BICR Per RECIST 1.1
MonthsPembrolizumab+LenvatinibPembrolizumab+Placebo
Duration of Response (DOR) as Assessed by BICR Per RECIST 1.126.9 (3.4 to NA)NA (NA to NA)
SecondaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The final analysis for this outcome is presented here.

Time frame:
Up to approximately 67 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsPembrolizumab+LenvatinibPembrolizumab+Placebo
Number of Participants With Adverse Events (AEs)331330
SecondaryNumber of Participants Who Discontinue Study Treatment Due to Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued any study treatment due to an AE is presented. The final analysis for this outcome is presented here.

Time frame:
Up to approximately 63 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Study Treatment Due to Adverse Events (AEs)
ParticipantsPembrolizumab+LenvatinibPembrolizumab+Placebo
Number of Participants Who Discontinue Study Treatment Due to Adverse Events (AEs)10468
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire-Core 30 [QLQ-C30] Global Health Status (GHS)/Quality of Life (QoL) Score

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The GHS/QoL combined score consists of participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" GHS/QoL responses range in score from 0 to 100, with a higher score indicating a better outcome. The final analysis for this outcome is presented here.

Time frame:
Baseline and Week 21
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire-Core 30 [QLQ-C30] Global Health Status (GHS)/Quality of Life (QoL) Score
Scores on a scalePembrolizumab+LenvatinibPembrolizumab+Placebo
Change From Baseline in European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire-Core 30 [QLQ-C30] Global Health Status (GHS)/Quality of Life (QoL) Score-6.38 (-8.91 to -3.84)-2.69 (-5.30 to -0.08)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Pembrolizumab+Placebo · cLDA model · p = 0.0345 (No formal hypothesis testing was conducted. P-value is nominal.) · Difference in ls means: -3.69 · 95% CI -7.10 to -0.27Difference in LS means=Pembrolizumab + Lenvatinib vs. Pembrolizumab + Placebo
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire-Core 30 [QLQ-C30] Physical Function (PF) Score

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The PF Score consists of participant responses to questions regarding PF (5 questions about daily activities \[strenuous activities, long walks, short walks, bed/chair rest and needing help with eating, dressing, washing themselves or using the toilet\]). For PF, responses range in score from 0 to 100, with a higher score indicating a better outcome. The final analysis for this outcome is presented here.

Time frame:
Baseline and Week 21
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire-Core 30 [QLQ-C30] Physical Function (PF) Score
Scores on a scalePembrolizumab+LenvatinibPembrolizumab+Placebo
Change From Baseline in European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire-Core 30 [QLQ-C30] Physical Function (PF) Score-9.50 (-11.66 to -7.34)-4.02 (-6.23 to -1.80)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Pembrolizumab+Placebo · cLDA model · p = 0.0004 · Difference in ls means: -5.49 · 95% CI -8.53 to -2.45Difference in LS means=Pembrolizumab + Lenvatinib vs. Pembrolizumab + Placebo
SecondaryTime to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 GHS/QoL Score

TTD is defined as the time from Baseline to 1st onset of a ≥10-point negative change (decrease) in EORTC-QLQ-C30 GHS Score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The GHS/QoL Score consists of participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" GHS/QoL responses range in score from 0 to 100, with a higher score indicating a better outcome. A longer TTD indicates a better outcome. The final analysis for this outcome is presented here.

Time frame:
Up to approximately 30 months
Reported as:
Median · Months
Time to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 GHS/QoL Score
MonthsPembrolizumab+LenvatinibPembrolizumab+Placebo
Time to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 GHS/QoL Score5.62 (4.34 to 9.69)24.58 (11.04 to NA)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Pembrolizumab+Placebo · Log Rank · p = 0.0001 · Hazard ratio (hr): 1.58 · 95% CI 1.25 to 2.00HR=Lenvatinib + Pembrolizumab vs. Placebo + Pembrolizumab
SecondaryTime to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 in Physical Function (PF) Score

TTD is defined as the time from Baseline to 1st onset of a ≥10-point negative change (decrease) in EORTC-QLQ-C30 PF Score. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The PF Score consists of participant responses to questions regarding PF (5 questions about daily activities \[strenuous activities, long walks, short walks, bed/chair rest \& needing help with eating, dressing, washing themselves or using the toilet\]. For PF, responses range in score from 0 to 100, with a higher score indicating a better outcome. The final analysis for this outcome is presented here.

Time frame:
Up to approximately 30 months
Reported as:
Median · Months
Time to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 in Physical Function (PF) Score
MonthsPembrolizumab+LenvatinibPembrolizumab+Placebo
Time to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 in Physical Function (PF) Score5.55 (4.40 to 9.69)NA (NA to NA)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Pembrolizumab+Placebo · Log Rank · p = .0001 · Hazard ratio (hr): 1.95 · 95% CI 1.52 to 2.50HR=Lenvatinib + Pembrolizumab vs. Placebo + Pembrolizumab

Adverse events

Collected over Up to approximately 67 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab+Lenvatinib206/334 (61.7%)124/332 (37.3%)326/332 (98.2%)
Pembrolizumab+Placebo176/340 (51.8%)96/338 (28.4%)319/338 (94.4%)
Most frequent serious events
Showing 10 of 201
Most frequent serious events
EventPembrolizumab+LenvatinibPembrolizumab+Placebo
DiarrhoeaGastrointestinal disorders6/3324/338
COVID-19 pneumoniaInfections and infestations3/3326/338
PneumoniaInfections and infestations5/3321/338
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/3320/338
COVID-19Infections and infestations2/3325/338
Acute myocardial infarctionCardiac disorders4/3320/338
PancreatitisGastrointestinal disorders4/3320/338
PyrexiaGeneral disorders4/3321/338
Acute kidney injuryRenal and urinary disorders4/3323/338
Adrenal insufficiencyEndocrine disorders3/3321/338
Most frequent other events
Showing 10 of 68
Most frequent other events
EventPembrolizumab+LenvatinibPembrolizumab+Placebo
HypertensionVascular disorders203/33275/338
DiarrhoeaGastrointestinal disorders171/33284/338
HypothyroidismEndocrine disorders157/33244/338
Decreased appetiteMetabolism and nutrition disorders113/33254/338
NauseaGastrointestinal disorders111/33261/338
ArthralgiaMusculoskeletal and connective tissue disorders100/33269/338
ProteinuriaRenal and urinary disorders100/33235/338
AstheniaGeneral disorders95/33282/338
FatigueGeneral disorders92/33286/338
Weight decreasedInvestigations91/33230/338

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pembrolizumab+LenvatinibPembrolizumab+PlaceboTotal
Mean61.8 ± 14.062.0 ± 13.161.9 ± 13.5
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab+LenvatinibPembrolizumab+PlaceboTotal
Female125139264
Male209201410
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab+LenvatinibPembrolizumab+PlaceboTotal
Hispanic or Latino7079149
Not Hispanic or Latino224225449
Unknown or Not Reported403676
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab+LenvatinibPembrolizumab+PlaceboTotal
American Indian or Alaska Native000
Asian554398
Native Hawaiian or Other Pacific Islander000
Black or African American134
White243261504
More than one race123
Unknown or Not Reported343165
Proto-oncogene B-Raf (BRAF) mutation positive
Proto-oncogene B-Raf (BRAF) mutation positive(Participants)Pembrolizumab+LenvatinibPembrolizumab+PlaceboTotal
No211215426
Yes123125248
08

Study locations

119 sites
  • The Angeles Clinic and Research Institute ( Site 0707)
    Los Angeles, California 90025, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0704)
    San Francisco, California 30322, United States
  • California Pacific Medical Center Research Institute ( Site 0705)
    San Francisco, California 94115, United States
  • John Wayne Cancer Institute ( Site 0706)
    Santa Monica, California 90404, United States
  • University of Colorado Cancer Center ( Site 0708)
    Aurora, Colorado 80045, United States
  • Yale Cancer Center ( Site 0709)
    New Haven, Connecticut 06510, United States
  • Baptist MD Anderson Cancer Center ( Site 0767)
    Jacksonville, Florida 32207, United States
  • Mid-Florida Cancer Centers ( Site 0764)
    Orange City, Florida 32763, United States
  • AMG Oncology ( Site 0714)
    Park Ridge, Illinois 60068, United States
  • Illinois Cancer Care, PC ( Site 0765)
    Peoria, Illinois 61615, United States
  • Minnesota Oncology Specialist, PA ( Site 0766)
    Fridley, Minnesota 55432, United States
  • St. Vincent Frontier Cancer Center ( Site 0724)
    Billings, Montana 59102, United States
  • Atlantic Health System ( Site 0768)
    Morristown, New Jersey 07960, United States
  • Valley Hospital ( Site 0749)
    Paramus, New Jersey 07652, United States
  • University of North Carolina - Cancer Hospital ( Site 0751)
    Chapel Hill, North Carolina 27514, United States
  • OHSU Center for Health & Healing ( Site 0731)
    Portland, Oregon 97239, United States
  • Inova Schar Cancer Institute ( Site 0739)
    Fairfax, Virginia 22031-4867, United States
  • Lismore Base Hospital ( Site 0453)
    Lismore, Australian Capital Territory 2480, Australia
  • Melanoma Institute Australia ( Site 0452)
    North Sydney, New South Wales 2060, Australia
  • Westmead Hospital ( Site 0451)
    Westmead, New South Wales 2145, Australia
  • Princess Alexandra Hospital ( Site 0454)
    Wooloongabba, Queensland 4102, Australia
  • Eastern Health ( Site 0457)
    Box Hill, Victoria 3128, Australia
  • Fiona Stanley Hospital ( Site 0456)
    Murdoch, Western Australia 6150, Australia
  • LKH Universitatsklinikum Graz ( Site 0776)
    Graz, Styria 8036, Austria
  • Medizinische Universitat Wien ( Site 0778)
    Vienna, 1090, Austria
  • PERSONAL - Oncologia de Precisao e Personalizada ( Site 0399)
    Belo Horizonte, Minas Gerais 30130-090, Brazil
  • Hospital de Caridade de Ijui ( Site 0391)
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Hospital Sao Vicente de Paulo ( Site 0396)
    Passo Fundo, Rio Grande do Sul 99010-080, Brazil
  • Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 0397)
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Instituto Nacional de Cancer Hospital do Cancer II ( Site 0394)
    Rio de Janeiro, 20220-410, Brazil
  • BC Cancer-Kelowna - Sindi Ahluwalia Hawkins Centre ( Site 0661)
    Kelowna, British Columbia V1Y 5L3, Canada
  • Lions Gate Hospital ( Site 0662)
    North Vancouver, British Columbia V7L 2L7, Canada
  • Sunnybrook Research Institute ( Site 0654)
    Toronto, Ontario M4N 3M5, Canada
  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0652)
    Montreal, Quebec H2W 3E4, Canada
  • McGill University Health Centre ( Site 0651)
    Montreal, Quebec H4A 3J1, Canada
  • Centro Investigación del Cáncer James Lind ( Site 0425)
    Temuco, Araucania 4780000, Chile
  • Fundacion Arturo Lopez Perez FALP ( Site 0421)
    Santiago, Region M. de Santiago 7500921, Chile
  • Pontificia Universidad Catolica de Chile ( Site 0422)
    Santiago, Region M. de Santiago 8330024, Chile
  • Sociedad Medica Aren y Bachero Limitada ( Site 0426)
    Santiago, Region M. de Santiago 8420383, Chile
  • Oncocentro ( Site 0424)
    Viña del Mar, Valparaiso 2520598, Chile
  • Beijing Cancer Hospital ( Site 0601)
    Beijing, Beijing Municipality 100036, China
  • Fujian Provincial Cancer Hospital ( Site 0612)
    Fuzhou, Fujian 350014, China
  • Sun Yat-Sen University Cancer Center ( Site 0602)
    Guangzhou, Guangdong 510000, China
  • Henan Cancer Hospital ( Site 0610)
    Zhengzhou, Henan 450003, China
  • Nanjing Drum Tower Hospital ( Site 0609)
    Nanjing, Jiangsu 210008, China
  • The First Hospital Of Jilin University ( Site 0603)
    Changchun, Jilin 130021, China
  • Fudan University Shanghai Cancer Center ( Site 0607)
    Shanghai, Shanghai Municipality 200032, China
  • Tianjin Medical University Cancer Institute & Hospital ( Site 0606)
    Tianjin, Tianjin Municipality 300060, China
  • Yunnan Cancer Hospital ( Site 0604)
    Kunming, Yunnan 430030, China
  • Sir Run Run Shaw Hospital ( Site 0605)
    Hangzhou, Zhejiang 310018, China
  • Zhejiang Cancer Hospital ( Site 0608)
    Hangzhou, Zhejiang 310022, China
  • Hopital ARCHET 2 ( Site 0009)
    Nice, Alpes-Maritimes 06200, France
  • Hopital La Timone ( Site 0002)
    Marseille, Bouches-du-Rhone 13385, France
  • CHU Dijon Bourgogne ( Site 0010)
    Dijon, Cote-d Or 21079, France
  • Institut Claudius Regaud IUCT Oncopole ( Site 0003)
    Toulouse, Haute-Garonne 31059, France
  • Hopital Ambroise Pare Boulogne ( Site 0007)
    Boulogne-Billancourt, Hauts-de-Seine 92100, France
  • CHRU Lille - Hopital Claude Huriez ( Site 0004)
    Lille, Nord 59037, France
  • CHU de Rouen ( Site 0013)
    Rouen, Seine-Maritime 76000, France
  • Centre Hospitalier Victor Dupouy ( Site 0012)
    Argenteuil, Val-d Oise 95100, France
  • Institut Gustave Roussy ( Site 0001)
    Villejuif, Val-de-Marne 94805, France
  • CHU de la Miletrie Poitiers ( Site 0011)
    Poitiers, Vienne 86021, France
  • Klinik fur Dermatologie Allergologie und Venerologie ( Site 0035)
    Hannover, Baden-Wurttemberg 30625, Germany
  • Universitaetsklinikum Erlangen ( Site 0044)
    Erlangen, Bavaria 91054, Germany
  • Universitaetsklinikum Wuerzburg-Department of Dermatology ( Site 0036)
    Würzburg, Bavaria 97080, Germany
  • Hautkrebszentrum Buxtehude ( Site 0037)
    Buxtehude, Lower Saxony 21614, Germany
  • Universitaetsklinikum Carl Gustav Carus ( Site 0041)
    Dresden, Saxony 01307, Germany
  • Universitaetsklinikum Leipzig ( Site 0040)
    Leipzig, Saxony 04103, Germany
  • Universitaetsklinikum Schleswig-Holstein Campus Kiel ( Site 0033)
    Kiel, Schleswig-Holstein 24105, Germany
  • SRH Wald-Klinikum Gera GmbH ( Site 0042)
    Gera, Thuringia 07548, Germany
  • HaEmek Medical Center ( Site 0306)
    Afula, 1834111, Israel
  • Soroka Medical Center ( Site 0303)
    Beersheba, 8457108, Israel
  • Rambam Medical Center ( Site 0301)
    Haifa, 3109601, Israel
  • Hadassah Ein Karem Hebrew University Medical Center ( Site 0305)
    Jerusalem, 9112001, Israel
  • Rabin Medical Center ( Site 0302)
    Petah Tikva, 4941492, Israel
  • Chaim Sheba Medical Center ( Site 0304)
    Ramat Gan, 5262000, Israel
  • Sourasky Medical Center ( Site 0307)
    Tel Aviv, 6423906, Israel
  • Shamir Medical Center-Assaf Harofeh ( Site 0308)
    Ẕerifin, 70300, Israel
  • ASST Papa Giovanni XXIII ( Site 0062)
    Bergamo, Abruzzo 24127, Italy
  • Azienda Ospedaliera Universitaria Senese ( Site 0065)
    Siena, Tuscany 53100, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0064)
    Milan, 20133, Italy
  • Istituto Europeo di Oncologia ( Site 0067)
    Milan, 20141, Italy
  • Istituto Nazionale Tumori Fondazione Pascale ( Site 0061)
    Naples, 80131, Italy
  • Istituto Oncologico Veneto ( Site 0063)
    Padova, 35128, Italy
  • Szpital Kliniczny im. Heliodora Swiecickiego Uniwers Medyczn ( Site 0272)
    Poznan, Greater Poland Voivodeship 60-780, Poland
  • Centrum Onkologii im.prof. F. Lukaszczyka w Bydgoszczy ( Site 0273)
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-796, Poland
  • Pratia MCM Krakow ( Site 0280)
    Krakow, Lesser Poland Voivodeship 30-510, Poland
  • Uniwersyteckie Centrum Kliniczne ( Site 0281)
    Gdansk, Pomeranian Voivodeship 80-214, Poland
  • Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 0278)
    Gliwice, Silesian Voivodeship 44-102, Poland
  • Cancer Care Langenhoven Drive Oncology Centre ( Site 0805)
    Port Elizabeth, Eastern Cape 6045, South Africa
  • Sandton Oncology Medical Group PTY LTD ( Site 0802)
    Johannesburg, Gauteng 2196, South Africa
  • Cape Town Oncology Trials Pty Ltd ( Site 0803)
    Kraaifontein, Western Cape 7570, South Africa
  • Kyungpook National University Chilgok Hospital ( Site 0553)
    Daegu, Taegu-Kwangyokshi 41404, South Korea
  • Seoul National University Hospital ( Site 0554)
    Seoul, 03080, South Korea
  • Severance Hospital Yonsei University Health System ( Site 0552)
    Seoul, 03722, South Korea
  • Samsung Medical Center ( Site 0551)
    Seoul, 06351, South Korea
  • Hospital Duran i Reinals ICO de Hospitalet ( Site 0187)
    Hospitalet Del Llobregat, Barcelona 08908, Spain
  • Hospital Universitario Marques de Valdecilla ( Site 0181)
    Santander, Cantabria 39008, Spain
  • Complejo Hospitalario Universitario A Coruna. CHUAC ( Site 0182)
    A Coruña, La Coruna 15006, Spain
  • Hospital Universitario Insular de Gran Canaria ( Site 0189)
    Las Palmas de Gran Canaria, Las Palmas 35001, Spain
  • Hospital Clinic i Provincial Barcelona ( Site 0190)
    Barcelona, 08036, Spain

Showing the first 100 of 119 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Arance A, Berciano-Guerrero MA, Guo J, Carlino MS, Ascierto PA, Burotto M, Mortier L, Queirolo P, Chiarion-Sileni V, Schachter J, Zhang X, Martin-Liberal J, Del Vecchio M, Okpara CE, Dutcus C, Zhang J, Diede SJ, Neff T, Long GV. Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma. Ann Oncol. 2025 Dec;36(12):1535-1546. doi: 10.1016/j.annonc.2025.08.008. Epub 2025 Aug 28. PubMed 40885529 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Jan 2023, 46 months.

Results were first posted in Jan 2024, 11 months after primary completion.

Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's 46 months is above that.

Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2019
First posted
Jan 29, 2019
StartActual
Mar 12, 2019
Primary completionActual
Jan 18, 2023
CompletionActual
Nov 1, 2024
Results first posted
Jan 17, 2024
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03820986
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Jan 29, 2019
Start date
Mar 12, 2019
Primary completion
Jan 18, 2023
Completion
Nov 1, 2024
Results posted
Jan 17, 2024
Last update
Feb 9, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion